Dr. Bradford brings over 25 years of experience in clinical research, including over 20 years in the biopharma industry in executive, development, and medical affairs roles. He was a co-founder of Cascadia Therapeutics, which was acquired by Indalo in 2016, and recently served as the Chief Medical Officer of Moerae Matrix. Dr. Bradford was Senior Vice President of Clinical Development at InterMune, where he was the architect of the Esbriet® clinical program and approvals for idiopathic pulmonary fibrosis. He has also held positions at IntraBiotics Pharmaceuticals and Genentech. Dr. Bradford trained in internal medicine and infectious diseases and practiced academic medicine at the University of California, San Francisco. He received his Ph.D. in epidemiology from the University of California, Berkeley, his M.D. from the University of North Carolina, Chapel Hill, and his B.A. from Williams College.